About Berry Flavonoid Pigments
Anthocyanins are the red/purple/blue flavonoid pigments in berries and fruits — the largest group of water-soluble plant pigments. Over 700 individual compounds exist; different berries deliver very different profiles (bilberry ≠ blueberry ≠ aronia ≠ blackcurrant). Multiple meta-analyses show consistent modest lipid improvements: LDL ↓5 mg/dL, TG ↓6 mg/dL, HDL ↑11 mg/dL. Significant acute and chronic FMD improvement. Uniquely strong epidemiological CVD signal — anthocyanins are the only flavonoid subclass significantly associated with lower CHD, CVD, and total mortality in large prospective cohort studies (Iowa Women's Health Study, NHS+HPFS). However, no RCT has tested hard CVD endpoints. ⚠️ Only ~1% reaches circulation as intact anthocyanin (~12% true bioavailability counting all metabolites). Effects likely mediated by gut microbial metabolites, creating massive inter-individual variability. Blood pressure and inflammation benefits appear stronger with whole berries than isolated anthocyanins (synergy with other polyphenols). Eye health/night vision claims — the most commercially exploited application — have the weakest evidence. Exceptionally safe; no serious adverse effects at any supplemental dose.
What Berry Flavonoid Pigments supports
- Consistent modest lipid improvement across meta-analyses (LDL ↓, TG ↓, HDL ↑) and strong epidemiological CVD association
- Improves vascular function (FMD) acutely and chronically via nitric oxide enhancement
- Only ~1% bioavailable as intact compound — effects depend heavily on individual gut microbiome and berry source
How much Berry Flavonoid Pigments to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
80–500
mg
General cardiovascular: 80–500 mg/day anthocyanins. Glycemic effects require >300 mg/day for >8 weeks. Bilberry eye products typically provide 36–160 mg/day anthocyanins. Purified supplements (e.g. Medox 80 mg) have the most targeted lipid data.
Clinical evidence
Moderate clinical evidence. Multiple meta-analyses show consistent modest lipid improvements; strong epidemiological CVD signal
NIH Fact Sheet